What's in Sung-Soo Park's pipeline?

Sung-Soo Park has 2 drugs in our index: 0 marketed, 0 filed, 0 in Phase 3, 2 in Phase 2, 0 in Phase 1.

Which companies overlap with Sung-Soo Park's portfolio?

Top competitors by shared drug class: Amgen, Sanofi, Allergan, AstraZeneca, Atom Therapeutics Co., Ltd.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/sung-soo-park.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-06-10 · How we verify

Sung-Soo Park — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Sung-Soo Park pipeline: 0 marketed, 0 filed, 0 Phase 3, 2 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 0 Phase 3 2 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

No leading-phase drugs tracked for this sponsor.

Therapeutic area mix

Oncology · 2

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Amgen · 2 shared drug classes
Sanofi · 2 shared drug classes
Allergan · 1 shared drug class
AstraZeneca · 1 shared drug class
Atom Therapeutics Co., Ltd · 1 shared drug class
BioNTech SE · 1 shared drug class
Coherus Oncology, Inc. · 1 shared drug class
Allakos Inc. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Sung-Soo Park:

Cite this brief

Drug Landscape (2026). Sung-Soo Park — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/sung-soo-park. Accessed 2026-06-10.